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possess immunosuppressive properties by selectively halting im-
mune cells at the G0-G1 phase of the cell cycle but only partially
affecting their effector function (split anergy). For these reasons
MSC have been used to manipulate graft-versus-host disease
(GvHD). We tested the therapeutic potentials of human MSC to
prevent and/or treat GvHD in a xenogeneic model. Sublethally
irradiated NOD/SCID mice were transplanted with CFSE-la-
belled human PBMC obtained from normal buffy coats. In a group
of mice MSC were given in a single infusion at the time of PBMC
infusion whilst in another group MSC were administered at weekly
intervals. Recipient mice were evaluated at serial intervals for
human T cells proliferation as measured by CFSE staining and
number of CD45/CD3 cells; clinical signs of GvHD (wasting,
rufﬂed hair, hunched back) were also monitored. At the end of the
experiment lymphoid and non lymphoid tissues were examined by
histological analysis. In control mice, the proliferation of human T
cells was already evident in the peripheral blood 3 weeks after
infusion and progressed thereafter. The mice started to develop
signs of GvHD after 8-10 weeks and the disease was then con-
ﬁrmed by histology. Lymphoid inﬁltrates were evident in lym-
phoid tissues as well as in liver, kidney, spleen, lung, and peritoneal
washing. The mice injected with a single dose of MSC at the time
of PBMC infusion did not behave differently form the controls.
However, when MSC were given at weekly intervals, there was a
marked decrease in human T cell engraftment and none of the
mice developed GvHD. If MSC were administered when GvHD
had already developed, T cell expansion and the course of the
disease were comparable to controls. MSC were tracked 10 days
after infusion by using cells which had been transduced with eGFP.
PCR analysis showed their presence only in the BM in mice
receiving only PBMC, but were distributed also in the lungs, liver
and peritoneal washing in the mice in which MSC were adminis-
tered with PBMC. Our study shows that the frequent administra-
tions of MSC prevent the development of GVHD but fails to treat
the disease when established. These ﬁndings are consistent with
the notion that the immunosuppressive effect of MSC resembles
split anergy, thus supporting the use of MSC as a prophylactic
rather than a therapeutic agent for GvHD.
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MULTIPOTENTIAL MESENCHYMAL STROMAL CELLS (MMSC) ABRO-
GATE ACUTE GRAFT-VERSUS-HOST DISEASE IN A MURINE MODEL
Lacy, J.1, Jackson, J.1, Murphy, B.1, Sharp, G.1, Devetten, M.1 1Uni-
versity of Nebraska Medical Center, Omaha, NE.
Acute Graft-versus-Host Disease (GVHD) remains a major com-
plication after allogeneic hematopoietic cell transplantation
(HCT). Several publications show a potential beneﬁcial effect of
human MMSC for the treatment of refractory GVHD. The mech-
anism of action remains to be determined. We set out to develop
an animal model that can be used to further study the effect of
MMSC on GVHD. MMSC were obtained from female C57Bl/6J
(H2b) mice by standard culture technique. ISCT criteria were used
to conﬁrm development of bona ﬁde MMSC by ﬂow cytometry
and by in-vitro differentiation experiments. GVHD was induced
by transplantation of C57Bl/6J donor bone marrow cells (5 
10E6) and spleen cells (6  10E6) into lethally irradiated DBA
(H2d) recipient mice. This model resulted in acute GVHD starting
at transplant day 10 with near-complete lethality by transplant
day 35. MMSC were infused at various doses on transplant day
10. Abrogation of GVHD was noted at all dose levels studied,
with complete rescue from lethality in the group receiving 1 
10E5 MMSC. Source of MMSC (donor, recipient, third party) did
not affect the beneﬁcial effect on GVHD. An MMSC cell line was
equally effective in providing abrogation of acute GVHD. We
conclude that a mouse model can be used to study the effect of
MMSC on acute GVHD.
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In T cell replete bone marrow transplantation GvHD remains a
major problem despite prophylaxis with immune suppressive
agents. In animal models CD4()CD25()FoxP3() T regulatory
(T reg) cells protected from rejection and GvHD after bone mar-
row transplantation. 70% of T reg are memory/effector cells with
a CD45RO phenotype. The others are naive CD45RA T cell.
When sorted and/or puriﬁed both subpopulations inhibit mixed
lymphocyte cultures. T cells from healthy subjects were enriched
by immnuselection to provide populations of CD45RA cells (95
%  2.9) and CD45RO cells (97 %  0.25). Naive and memory
cells were cultured in presence of human mesenchymal cells
(hMSC) (ratio 5:1). After 7 days’ culture, in the naive population
the T reg starting fraction of 0.05 %  0.01 of CD4/CD25
positive cells, rose to 0.2 %  0.14 in presence of MSC. In the
memory population the T reg starting fraction of 0.3 %  0.05 of
CD4/CD25 positive cells, rose to 1.5 %  0.9 in the presence of
MSC. The naive T reg starting fraction expressed 3 %  1.2
CD127 which was down-regulated to 0.29 %  0.2 with MSC.
Memory T reg cells expressed CD127 in 15% 1.2 of the starting
fraction which was down-regulated to 1.32 %  0.34 with MSC.
FoxP3 expression was measured by real time quantitative PCR in
sort-puriﬁed subsets of peripheral blood, identiﬁed by staining
with a combination of CD4, CD25, CD45RA or CD45RO. FoxP3
expression increased 1.15 fold in the presence of MSC in naive T
reg and 1.14 fold in memory T reg. Observing that naive and
memory T regulatory cells respond to MSC regulation opens new
perspectives for clinical use. Post transplant infusion of MSC
and/or donor regulatory cells after co-culture with MSC might be
a new option for GvHD treatment.
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Transplantation with haploidentical peripheral blood stem cells
from a parent are an acceptable form of treatment for children who
require stem cell transplantation but lack a conventional donor.
However, the risk of graft dysfunction increases due to the intense
T cell depletion of CD34 positive stem cell selection. Mesenchy-
mal stem cells (MSCs) isolated from bone marrow can improve
hematological recovery but their role in overcoming graft dysfunc-
tion post transplant is unknown.
We conducted an ethically committee approved prospective
study of co-transplantation of MSCs in children undergoing haplo-
identical PBSCT.
MSCs, isolated from haploidentical parental donor marrow were
expanded under GMP conditions 4-5 weeks before transplantation.
MSCs 1-2 106/kg recipient weight (fresh or cryopreserved) were
administered i.v. 4 hours before same donor G-CSF mobilized
PBSCs. To date, 10 children have been treated in two centers.
Conditioning depended on underlying disease. No additional
GvHD prophylaxis was given. Engraftment and immune recovery
was compared to historical controls (n48).
Characteristics and results are summarized in Table 1. No failure
of donor MSC expansion was seen. No acute toxicities were ob-
served during the infusion of MSC’s. There was no difference for
gender, age, donor type, CD34 or CD3 cells infused. Com-
pared to controls (23% graft dysfunction) all patients had 100%
documented, sustained engraftment. Hematological recovery of
leucocytes was faster ([p0,008] lymphocyte  neutrophil recov-
ery). Viral reactivations commonly occurred in both patients and
controls. Acute GvHD was 12.5% in the patient group compared
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to 39.5% of eligible controls. Three patients died, (1 relapse, 2
infection) compared to 17 controls (9 relapse, 5 infection, 3
GvHD). Longer follow-up and immune recovery data are continu-
ing.
MSC use is feasible and safe without infusional toxicities and, as
our study seems to suggest, stabilize engraftment. Based on our
ﬁndings, where graft dysfunction, delayed hematological (immune)
recovery compromise the success of stem cell transplant outcome,
clinical randomized studies of MSCs are warranted.
Table 1 Patient characteristics and summary of results
PATIENTS
(n10)
CONTROLS
(n48)
Male:Female 6 (60%): 4 (40%) 29 (60%): 19 (40%)
Age (range) 8 years (2 – 15) 8 years (6 mo –18)
Malignant 7 (70%) 34 (70%)
Immune 2 (25%) 6 (13%)
Benign 1 (13%) 8 (17%)
Donor Male:Female 5:3 24:24
CD34 infused 31.8 (SD 3.1) 20 (SD 6.8). NS
CD3 infused 0.3 (SD 0.30) 0.68 (SD 0.7). NS
Overall survival
7/10 (70%)
FU 3-48 mo
31/48 (64%)
FU 2-6y
Days to Leukocyte
>1.0  109/l 12 (SD 1.9) 18 (SD 3.3) p0.0005
Days to Neutrophil
>0.5  109/l 13 (SD 1.5) 15 (SD 3.6) p0.14
Days to Platelets
>20  109/l 13 (SD 2.7) 21 (SD 14.7) p0.08
Days to Reticulocytes
>20 15 (SD 4.9) 35 (SD14.9) p0.04
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Seven patients, 3 leukemics, 2 patients with severe aplastic ane-
mia (SAA) and 2 SCID patients, underwent co-transplantation
with mesenchymal stem cells (MSC) and hematopoietic stem cells
(HSC). MSC were given in a pilot study to 4 patients and for graft
failure and retransplantation to 3 patients. HSCT donors were 3
HLA-identical siblings and 4 unrelated (2 matched and 1 major
mismatched unrelated and 1 mismatched unrelated cord blood).
Conditioning was myeloablative in 4 patients and RIC in 3 pa-
tients. MSC donors were HLA-identical siblings in 3 cases and
haploidentical in 4 cases. Passage 2-3 MSC were given at a dose of
1106/kg patient weight within 4 hours of the HSCT graft.
ANC 0.5109/L was reached in a median of 12 (range 10-28)
days. Platelets 30109/L was achieved in a median of 12 (8-36)
days. All patients had 100% donor chimerism for CD3, CD19 and
CD33 within 100 days. Acute GvHD grade 0-I was seen in 5
patients, two patients had grade II one proceeded to chronic
GvHD. One patient died of aspergillosis, the other patients are
alive and well.
One patient with SAA was on Cyclosporin for Henoch-Scho¨nlein
purpura since many years. This and graft failure resolved after
retransplantation of MSC  HSC.
Conclusion: MSC co-transplantation resulted in fast engraft-
ment of ANC and platelets and 100% donor chimerism, even in 3
patients regrafted for graft failure/rejection.
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Bone marrow or blood stem cell transplantation is the only cure
for 	-thalassemia major, however, despite myeloablative condi-
tioning regimens, the basic difﬁculty is a 15-30% graft failure rate
in these patients. Our hypothesis is that there may be a T-cell
dependent graft-versus-myelon effect that establishes and stabilizes
the engraftment of allogeneic blood stem cells in patients with
thalassemia major.
In a ﬁrst attempt, we assessed the CD3 chimerism early after
transplantation in a pediatric case series of six transplantations (2
related, 4 unrelated donors) transplanted from 2001 to 2004 with a
minimum follow-up period of 2 years after transplantation. The
donors were fully matched at HLA-DRB1 (high resolution) and
HLA-A and -B (low resolution). Peripheral blood CD3 chimerism
was determined at day30 (median). Chimerism of unfractionated
WBC was determined patients beginning day 13 (median) and
repeated until a stable engraftment or graft failure was achieved.
Patients (n  4) with a CD3 donor chimerism of 80% estab-
lished a long term engraftment and remained free of erythrocyte
transfusions (days 133, 775, 815, 2033). Two of these
patients developed a low total chimerism (minimum 42% on day
93, and 45% on day 42, resp.) after that a higher total donor
chimerism had been achieved (90% on day 17 and 92% on day
20, resp.). We stopped the immunosuppressive therapy in both
patients as soon as the result of the CD3 chimerism was available.
Both patients increased their total chimerism up to 98%; one
developed GvHD II° of the skin that resolved after steroid therapy
without impairment of the total chimerism.
Two patients with a CD3 donor chimerism10% lost their graft
completely, despite the fact, that one patient showed a high total
chimerism of 89% on day 6. One patient is again on the eryth-
rocyte transfusion programme, the other engrafted after re-trans-
plant from an unrelated donor.
We conclude that early determination of the CD3 chimerism
may be helpful for patient management. In addition, monitoring of
the CD3 chimerism should be included in transplant protocols for
beta-thalassemia major.
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Background
Allogeneic hematopoietic stem cell transplantation is a well es-
tablished treatment for hematological malignancies and other con-
ditions which can be associated with signiﬁcant morbidity and
mortality, particularly the development of severe acute graft-ver-
sus-host disease (GVHD). Severe steroid-refractory acute GVHD
continues to be associated with an 80-90% mortality despite the
use of many immunosuppressive agents with differing modes of
action. Mesenchymal stem cells (MSC) are rare, non-hemopoietic
cells found in the bone marrow, capable of differentiation into
bone, cartilage, muscle and fat cells. In addition to their potential
role in tissue repair, MSC have unique immunomodulatory prop-
erties. In vitro studies demonstrate they are both non-immuno-
genic and immunosuppressive. These property have been exploited
in the treatment of severe aGVHD. LeBlanc et al reported the ﬁrst
case of the successful treatment of steroid-refractory GVHD with
MSC in 2004 and in a recently reported EBMT study an overall
response rate of 69% was seen in 28 patients with steroid refractory
aGVHD. We report our experience with the use of MSC for
GVHD in 3 patients over the last 7 months.
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